Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Where Might Investigational Long-Acting 2-Drug Combinations of ARVs With Novel Mechanisms of Action Fit Into the Future HIV Treatment Landscape?

Karine Lacombe, MD, PhD

Professor
UMR-S1136
Sorbonne University
Professor
Infectious Diseases Department
St Antoine Hospital
Paris, France


Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Chiesi, Gilead Sciences, and Janssen.


View ClinicalThoughts from this Author

Released: November 30, 2021

The advent of HIV drugs with new modes of action has considerably broadened the landscape of options for heavily treated patients harboring multidrug-resistant viral variants. Several investigational drugs in the later stages of development offer the promise of further expanding options for these patients, including the potential for long-acting 2-drug regimen options. In fact, the benefits of long-acting 2-drug regimens involving antiretrovirals (ARVs) with novel mechanisms of action would not be limited to patients with extensive treatment experience.

What Needs Could Be Addressed by a Long-Acting 2-Drug Regimen Involving 2 ARVs With Novel Mechanisms of Action?
In considering the potential for ARVs with novel mechanisms of action to provide a potent, long-acting 2-drug regimen with a high barrier to resistance and a strong safety profile, the relevant patient populations would be quite broad. First, such a regimen would be ideal for patients receiving long-term antiretroviral therapy (ART) with a history of nonadherence or regimen shortcomings that have led to multidrug resistance. The further development of an injectable form of a regimen with these characteristics also may help patients who are reluctant to take a long-term oral treatment. Although ibalizumab and fostemsavir each were designed to provide much-needed options for heavily treatment-experienced patients and each have proven effective in combination with optimized background regimens, a 2-drug combination involving 2 novel drug classes may allow the elimination of the optimized background regimen in this setting. 

Similar to the role of the new long-acting 2-drug regimen of injectable cabotegravir plus rilpivirine, a long-acting 2-drug regimen that included ARVs with novel mechanisms of action would be attractive as a switch strategy in virologically suppressed patients. Such a regimen would provide an additional option for patients who need to switch away from drugs with safety/tolerability concerns such as weight gain (newer-generation integrase strand transfer inhibitors and tenofovir alafenamide), kidney and bone toxicity (tenofovir disoproxil fumarate), or lipid abnormalities (protease inhibitors). If the regimen harbored a favorable drug‒drug interaction profile, it would also have a potential role for patients with polypharmacy because of comorbidities.

ART-naive patients make up the third group of patients who also could benefit from a long-acting 2-drug regimen that included ARVs with novel mechanisms of action. For treatment-naive patients, the arrival of oral 2-drug regimen strategies has disrupted the treatment paradigm of highly active ART based on 3 potent drugs, which has prevailed for many years. The availability of a 2-drug combination that could be delivered either orally or parenterally with long-acting kinetics, a high barrier to resistance, and a favorable safety profile would likely be appealing to newly diagnosed patients, particularly for several key populations whose needs have not been sufficiently met by the current daily oral ART options. Who are those patients? They include men who have sex with men who may have experienced a failure of oral pre-exposure prophylaxis (PrEP) and/or would experience considerable benefit from having their HIV treatment adapted to their lifestyles and preferences, rather than the treatment requiring them to adapt, a condition imposed on them in many other ways through deeply rooted societal constraints. Another important group includes vulnerable individuals from often underserved populations, such as migrants or transgender women, who are at high risk of acquiring HIV and are prone to difficulties with daily oral medication adherence primarily because of socioeconomic disparities. For these patients, offering a potent, long-acting 2-drug regimen may be a substantial asset for long-term HIV control.

LEN Plus ISL as a Potential Long-Acting 2-Drug Regimen
Lenacapavir (LEN) is a first-in-class capsid inhibitor that binds to capsid subunits and interferes with capsid assembly during virus production and with capsid disassembly after transport of reverse transcription products into the nucleus. This unique ability plus its long half-life led to the clinical evaluation of a weekly oral 2-drug regimen combining LEN with islatravir (ISL), another investigational drug with a novel mechanism of action and long-acting dosing potential. ISL is a first-in-class nucleoside reverse transcriptase translocation inhibitor. In phase II trials that evaluated LEN and ISL separately in different treatment contexts, each was highly potent with no major safety concerns originally reported. ISL has been evaluated in phase II trials as a daily oral formulation in combination with doravirine for initial HIV treatment and as an oral once-monthly formulation for use as HIV pre-exposure prophylaxis (PrEP), whereas LEN has been evaluated as a SC formulation given every 6 months (following an oral lead-in) in a phase II/III trial in combination with an optimized background regimen for patients with extensive antiretroviral therapy (ART) experience and in a phase II trial in combination with daily oral tenofovir alafenamide (TAF) or daily oral bictegravir for initial HIV treatment. These studies have targeted several unmet needs in HIV treatment and prevention, including the need for long-acting PrEP options and for longer-acting treatment options in heavily treatment-experienced patients. However, essentially all clinical trials involving ISL have been placed on full or partial clinical hold by the FDA as of December 2021. The hold is based on decreases in total lymphocyte and CD4+ cell counts observed in some participants receiving ISL in clinical studies. Although the future of this particular long-acting 2-drug combination remains to be determined, it represents an example of the type of regimen that could address the unmet needs outlined herein.

Closing Thoughts?
In summary, the investigation of long-acting 2-drug HIV treatment regimens involving ARVs with novel mechanisms of action offers great potential for a variety of patient populations, including treatment-experienced patients in search of potency and good tolerability who either are experiencing failure of their current regimen or are needing to switch from a virologically suppressive regimen and ART-naive patients for whom efficacy and convenience are paramount. Of course, these proposed roles depend on the availability of clinical trial data supporting the essential characteristics of such a regimen—specifically high potency, a strong safety/tolerability profile, and a high genetic barrier to resistance.

Your Thoughts?
Which of the developing 2-drug ART regimens are you most excited to be able to offer your patients if they are approved? Answer the polling question and join the discussion by posting a comment. For more discussion of current and future HIV treatment, comorbidities, prevention, and COVID-19–related issues, download the slides and watch the videos from our recent HIV Annual Update symposium.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings